Characteristics of patients enrolled
| Patients enrolled | 21 | |
| Median age, y | 70.4 | Range 53 to 85 |
| M/F ratio | 1/2 | |
| Associated B-cell disorder | 9/21 (42.9%) | B-CLL: 3 B-cell NHL: 6 |
| Previous treatments | ||
| Corticosteroids | 9 | |
| Rituximab | 12 | |
| Cyclophosphamide | 3 | |
| Azathioprine | 1 | |
| Splenectomy | 1 | |
| Hgb concentration (median) | 87 g/L | Range 78-102 |
| Transfusion dependence | 10/21 (47.6%) | |
| Monoclonal gammopathy at serum electrophoresis | 13/20* (65%) | Ig isotype: Mk 11, Gk 1, Mk+Gl 1 Paraprotein level <10% of total serum proteins in all 13 cases |
| Clonal B-cell disorder | ||
| Detectable clonal B cells in PB | 7/19* (36.8%) | Number of clonal B cells: 15-339/μL |
| B-lymphoid marrow infiltrate | 9/21 (42.9%) | Lymphoid infiltrate: 5%-15% of total cellularity |
| No evidence of monoclonal gammopathy nor of clonal B-cell disorder | 6/20* (30%) | |
| Comorbidities | ||
| Cardiovascular | 6 | Atrial fibrillation (1), chronic ischemic disorder (3), arterial hypertension (2), ictus cerebri (1) |
| Metabolic | 5 | Diabetes (3), hypothyroidism (1), osteoporosis (1) |
| Hepatic | 3 | Prior HBV infection (1), chronic HCV hepatitis (2) |
| Neoplastic | 3 | Breast cancer (2), thyroid papillary carcinoma (1) |
| Patients enrolled | 21 | |
| Median age, y | 70.4 | Range 53 to 85 |
| M/F ratio | 1/2 | |
| Associated B-cell disorder | 9/21 (42.9%) | B-CLL: 3 B-cell NHL: 6 |
| Previous treatments | ||
| Corticosteroids | 9 | |
| Rituximab | 12 | |
| Cyclophosphamide | 3 | |
| Azathioprine | 1 | |
| Splenectomy | 1 | |
| Hgb concentration (median) | 87 g/L | Range 78-102 |
| Transfusion dependence | 10/21 (47.6%) | |
| Monoclonal gammopathy at serum electrophoresis | 13/20* (65%) | Ig isotype: Mk 11, Gk 1, Mk+Gl 1 Paraprotein level <10% of total serum proteins in all 13 cases |
| Clonal B-cell disorder | ||
| Detectable clonal B cells in PB | 7/19* (36.8%) | Number of clonal B cells: 15-339/μL |
| B-lymphoid marrow infiltrate | 9/21 (42.9%) | Lymphoid infiltrate: 5%-15% of total cellularity |
| No evidence of monoclonal gammopathy nor of clonal B-cell disorder | 6/20* (30%) | |
| Comorbidities | ||
| Cardiovascular | 6 | Atrial fibrillation (1), chronic ischemic disorder (3), arterial hypertension (2), ictus cerebri (1) |
| Metabolic | 5 | Diabetes (3), hypothyroidism (1), osteoporosis (1) |
| Hepatic | 3 | Prior HBV infection (1), chronic HCV hepatitis (2) |
| Neoplastic | 3 | Breast cancer (2), thyroid papillary carcinoma (1) |
B-CLL, B-cell chronic lymphocytic leukemia; F, female; HBV, hepatitis B virus; HCV, hepatitis C virus; M, male; NHL, non-Hodgkin lymphoma; PB, peripheral blood.
Number of evaluable patients.